Chipman Christopher Michael 4/A
4/A · Virpax Pharmaceuticals, Inc. · Filed Feb 25, 2022
Insider Transaction Report
Form 4/AAmended
Chipman Christopher Michael
Chief Financial Officer
Transactions
- Award
Stock Option (right to buy)
2022-01-31+60,676→ 60,676 totalExercise: $2.13Exp: 2032-01-31→ Common Stock (60,676 underlying)
Footnotes (1)
- [F1]The option vests in three equal annual installments commencing on January 31, 2023.